Nuvisan Has Agreed to Sell 49% of its Shares to ALS

Thursday, July 29, 2021

Nuvisan (logo) has agreed to sell 49% of its shares to ALS (logo)

William Blair acted as the exclusive financial advisor to NUVISAN Gruppe, a founder-owned company, in connection with its pending minority sale to ALS Limited. The transaction was signed on July 27, 2021 and is expected to close in Q4 2021.

Transaction Highlights

  • Deep sector knowledge: Nuvisan was attracted to William Blair’s extensive knowledge and highly relevant transaction experience advising leading companies in the pharmaceutical services space.
  • Instrumental guidance and expert input: Following an unsolicited inbound from ALS, the transaction team was deeply involved throughout the bilateral transaction process, collaborating closely with management and providing guidance on overall process strategy and negotiations.
  • Significant transaction complexity: The high degree of complexity in the transaction structure required continuous guidance and input from the deal team, leading to the successful negotiation of the shareholder’s agreement and various option agreements.
  • Highly strategic transaction: The transaction will enable ALS to build upon its core capabilities in testing and inspection services, unlocking significant synergy opportunities. The contract pharmaceutical services market is a large, growing, attractive market, and Nuvisan gives ALS a strong foundation to build upon while enhancing its portfolio diversity and financial returns.

About the Companies

Founded in 1979, Nuvisan Gruppe is privately owned with over 900 employees and generated ~€185 million of revenue and ~€40 million of adjusted EBITDA in FY21. Nuvisan operates in contract research organisation and contract development and manufacturing organisation markets providing drug testing services throughout the pharmaceutical development cycle in the fast-growing outsourced market. The company is based in Neu-Ulm, Germany and operates seven sites across Germany and France.

ALS Limited is a publicly listed entity on the Australian stock exchange with a market capitalization of ~€3.8 billion. The company operates one of the world’s largest analytical and testing services businesses, spanning across major sectors including mining, natural resources, environmental, food, pharmaceutical, industrial and inspection services.

Learn more about our healthcare services investment banking expertise.

News Alerts

Stay connected to your favorite publications and news features.

Subscribe Now